Volume 9 Number 1 2026
Engineering Personalized Microbiome Medicine from Gut Metagenomes to Clinical Bioactives
Normurodova Kunduz Togaevna 1*, Vakhabov Abdurasul Khakimovich 1, Tashmukhamedova Shokhista Sabirovna 1, Shurygin Vyacheslav Vladimirovich 1
Microbial Bioactives 9 (1) 1-20 https://doi.org/10.25163/microbbioacts.9110930
Submitted: 12 July 2026 Revised: 01 September 2026 Accepted: 08 September 2026 Published: 10 September 2026
The human gut is now understood less as a passive tube and more as a densely populated, metabolically active organ in its own right — one whose genetic repertoire dwarfs that of its host. When this ecosystem drifts into dysbiosis, the consequences ripple outward into inflammatory, metabolic, and even neuropsychiatric disease. What has changed in the last decade, though, is not simply our awareness of this relationship but our capacity to measure it, model it, and — increasingly — to intervene in it with rational, patient-specific precision. We conducted a structured narrative synthesis of the peer-reviewed literature (2017–2026) addressing metagenomic and multi-omics profiling, computational and machine-learning platforms, and clinical bioactive design in the gut microbiome. Across the synthesized evidence, dysbiosis emerged as a structured — not stochastic — ecological state, reproducibly separable from eubiotic communities using ordination and machine-learning classifiers, with diagnostic performance reaching an area under the curve of 0.98 when metagenomic and metabolomic layers were fused. Genome-scale metabolic reconstructions predicted individualized short-chain fatty acid deficits and successfully guided personalized prebiotic supplementation in the majority of simulated Crohn's disease patients. Engineered live biotherapeutics and nanoparticle-based delivery platforms demonstrated proof-of-concept safety and target-specific payload release in early clinical and preclinical work, though translational reach remains constrained by sample-collection heterogeneity and a pronounced geographic skew in reference databases. Personalized microbiome medicine is arguably no longer a speculative frontier; the computational scaffolding and biological rationale are largely in place. What now stands between bench and bedside is less a scientific gap than an infrastructural one — standardization, validation, and equitable data representation.
Keywords: Gut microbiome; Metagenomics; Multi-omics integration; Precision medicine; Live biotherapeutic products; Machine learning; Genome-scale metabolic modeling.
Abdul Manan, M. (2025). The role of probiotics in personalized therapeutics: Advances in gut microbe-driven interventions. The Microbe, 8, Article 100497. https://doi.org/10.1016/j.microb.2025.100497
Alexandrescu, L., Tofolean, I. T., Condur, L. M., Tofolean, D. E., Nicoara, A. D., Serbanescu, L., Rusu, E., Twakor, A. N., Dumitru, E., Dumitru, A., Tocia, C., Herlo, L. F., Alexandrescu, D. M., & Stanigut, A. M. (2025). Smart microbiomes: How AI is revolutionizing personalized medicine. Bioengineering, 12(9), Article 944. https://doi.org/10.3390/bioengineering12090944
Amiri, D., Briziarelli, L., Shah, S. J., Karlsson, B., Amiri, S., Vakili, A., & Mustakova, A. (2026). Methodological heterogeneity and reproducibility in psychiatric microbiomics. Journal of Affective Disorders Reports, 25, Article 101133. https://doi.org/10.1016/j.jadr.2026.101133
Andrews, S. (2010). FastQC: A quality control tool for high throughput sequence data. Babraham Bioinformatics.
Bauer, E., & Thiele, I. (2018). From metagenomic data to personalized in silico microbiotas: Predicting dietary supplements for Crohn's disease. npj Systems Biology and Applications, 4, Article 27. https://doi.org/10.1038/s41540-018-0063-2
Cai, J., Auster, S., Cho, S., Leone, V., Hubert, N., Chang, E., & Dumas, M. E. (2023). Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage. Journal of Advanced Research, 52, 171–201. https://doi.org/10.1016/j.jare.2023.07.002
El-Sehrawy, A. A. M. A., & Soleimani Samarkhazan, H. (2026). Translational oncology: The gut microbiota in cancer immunity and immunotherapy. Translational Oncology, 70, Article 102833. https://doi.org/10.1016/j.tranon.2026.102833
Fousekis, F., Lianos, G. D., Stavropoulou, E., Patrikiou, E., Vradelis, S., Cassimos, D., & Tsigalou, C. (2026). Decoding gut microbiome alterations in celiac disease: Implications for pathogenesis and treatment. Autoimmunity Reviews, 104127.. https://doi.org/10.1016/j.autrev.2026.104127
Gibbons, S. M., Gurry, T., Lampe, J. W., Chakrabarti, A., Dam, V., Everard, A., Goas, A., Gross, G., Kleerebezem, M., Lane, J., Maukonen, J., Penna, A. L. B., Pot, B., Valdes, A. M., Walton, G., Weiss, A., Zanzer, Y. C., Venlet, N. V., & Miani, M. (2022). Perspective: Leveraging the gut microbiota to predict personalized responses to dietary, prebiotic, and probiotic interventions. Advances in Nutrition, 13(5), 1450–1461. https://doi.org/10.1016/j.advnut.2022.08.002
Hussain, A., Ilyas, R., Tasleem, S., Mojgani, N., Shah, H., & Ali, S. A. (2026). Integrated probiotic, nanotechnology, and artificial intelligence-based strategies for the management of multidrug-resistant pathogens: A review. Next Nanotechnology, 10, Article 100685. https://doi.org/10.1016/j.nexnan.2026.100685
Jalalifar, S., Bajelan, B., Mohammadi, R., Ghafoury, R., Kalhori, Z., Pooshang-Bagheri, K., ... & Faranoush, M. (2026). The impact of gut microbiota on leukemia and prospects for novel therapies. Infectious Medicine, 100239.
Jeyavelkumaran, R., Saravanan, M. D., Keerthivasan, N., Jeya, S. H., & Kumaran, J. (2026). Machine learning driven multi omics and probiotic integration for precision colorectal cancer management. Biomedical Analysis, 3, 24–37. https://doi.org/10.1016/j.bioana.2026.05.002
Kashyap, P. C., Chia, N., Nelson, H., Segal, E., & Elinav, E. (2017). Microbiome at the frontier of personalized medicine. Mayo Clinic Proceedings, 92(12), 1855–1864. https://doi.org/10.1016/j.mayocp.2017.10.004
Kharb, A., & Zhu, X. (2026). Unlocking therapeutic impacts of the gut microbiota with computational tools. Current Opinion in Biotechnology, 97, Article 103431. https://doi.org/10.1016/j.copbio.2025.103431
Moshref-Javadi, M., Ahmadbeigi, G., Ataollahi, H., Boroomand, S., Kheradmand Kia, S., Soleimani, N., Zia-Jahromi, N., & Hedayati, M. (2026). Bidirectional microbiota-cancer crosstalk: Emerging platforms for advanced diagnostics and precision therapeutics in oncology. Biomedicine & Pharmacotherapy, 201, Article 119745. https://doi.org/10.1016/j.biopha.2026.119745
Murugan, S., Kannan, S., Balakrishnan, J., & Bhosale, N. K. (2026). Therapeutic applications of nano-microbiome interactions. Medicine in Microecology, 30, Article 100184. https://doi.org/10.1016/j.medmic.2026.100184
Nair, V., Vijayakumar, K., Balakrishnan, J., & Suganya, K. (2026). Gut-targeted nutraceutical delivery: Engineering microbiome-responsive nutraceutical interfaces. Next Materials, 13, Article 103125. https://doi.org/10.1016/j.nxmate.2026.103125
Puig-Castellví, F., Pacheco-Tapia, R., Deslande, M., Jia, M., Andrikopoulos, P., Chechi, K., Bonnefond, A., Froguel, P., & Dumas, M. E. (2023). Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications. Trends in Analytical Chemistry, 167, Article 117248. https://doi.org/10.1016/j.trac.2023.117248
Rahimah, S., Tallei, T. E., Savitri, M., Yamada, C., Kim, H. J., Choi, M., Park, M. N., Ophinni, Y., & Kim, B. (2026). Modular model of precision nutrition: Integrating host genetics, epigenetics, and the gut microbiota. Food Chemistry: Molecular Sciences, 12, Article 100411. https://doi.org/10.1016/j.fochms.2026.100411
Rajak, M., Dash, D., & Koiri, R. K. (2026). Microbiota-derived metabolites in cancer: Dual roles in pathogenesis and opportunities for therapy. Medicine in Drug Discovery, 29, Article 100245. https://doi.org/10.1016/j.medidd.2025.100245
Sabit, H., Yadav, A. K., Salimy, S., Sakr, A., Abdel-Ghany, S., Wadan, A. S., Alqosaibi, A. I., Rashwan, R., AlGosaibi, Y. S., Alnamshan, M. M., Almulhim, J., Alaqeel, N. K., & Arneth, B. (2026). Integrative multi-omics and AI in precision breast cancer management. Cancer Letters, 649, Article 218468. https://doi.org/10.1016/j.canlet.2026.218468
Sharma, I., Bharti, S., Pandey, S., Gupta, S., Bisen, P. S., Kango, N., & Sharma, K. K. (2026). Leveraging computational methodologies for probiotic research: Unraveling host-microbiota interactions and therapeutic potential. Food Nutrition, 2, Article 100067. https://doi.org/10.1016/j.fnutr.2026.100067
Sun, C., Zhu, J., Sun, X., Zhang, Z., Sun, Y., Jin, Y., & Wu, T. (2026). Targeting the human gut microbiome: A comparative review of probiotics, prebiotics, synbiotics, and postbiotics. Journal of Advanced Research, 87, 727–752. https://doi.org/10.1016/j.jare.2025.12.025
Sutanto, H., & Fetarayani, D. (2026). Engineering the gut microbiome: Synthetic biology approaches for human health and disease. Gut Microbiology, 2, Article 100005. https://doi.org/10.1016/j.gutmic.2026.100005
Wu, Y., Zhang, K., Xu, B., Zengin, G., & Li, M. Y. (2026). Challenges and future perspectives in microbiome-metabolism-based therapeutics. TransMed, 1, Article 100032. https://doi.org/10.1016/j.tmed.2026.100032
Engineering the Gut Ecosystem by Precision-Designed Probiotics and Synthetic Microbial Consortia as Programmable Living Therapeutics
Sex and Gender Differences in Drug Response as an Underused Variable in Precision Medicine
Probiotics as Unintended Vectors of Horizontal Gene Transfer, the Gut Resistome, and the Biosafety of Live Biotherapeutic Products